Hengrui Medicine announced that it has been approved for a phase 3 clinical trial (combo therapy) of Rivoceranib (Apatinib, brand name Aitan®) aimed at first-line lung cancer treatment. Last month, Hengrui Medicine was approved for the Rivoceranib phase 3 clinical trial (Gefitinib combo) to target first-line non-small cell lung cancer treatment and this time, they were approved for the first-line non-small cell lung cancer treatment phase 3 approval (Camrelizumab combo).

An official said, “Hengrui Medicine seems to be promoting a commercial phase 3 clinical trial for non-small cell lung cancer based on several excellent clinical trial results" and indicated that the strength of Rivoceranib as an optimized drug for combination therapy was confirmed once again.

In February, HLB signed an agreement with Advenchen Laboratories to acquire Rivoceranib's global rights, including China. Recently, Hengrui Medicine has applied for a commercial license for Rivoceranib as a second-line liver cancer treatment in China, and as various indications such as a phase 3 lung cancer clinical trial have been expanded, expectations for an increase in royalty income of HLB are also increasing.